

# **Cancer Immunology Immunotherapy**

Founding Editor  
G. Mathé

Other Biological Response Modifications

Volume 21 1986

## **Editors in Chief**

**R. W. Baldwin E. Mihich**

## **Editorial Board**

**R. Bast** Durham  
**T. Boon** Brussels  
**E. C. Borden** Madison  
**T. Carey** Ann Arbor  
**M. Cheever** Seattle  
**G. A. Currie** Oxted, Surrey  
**W. Den Otter** Utrecht  
**J. E. de Vries** Amsterdam  
**S. Dray** Chicago  
**S. Eccles** Sutton, Surrey  
**I. Fidler** Houston  
**A. Goldstein** Washington

**E. Grimm** Bethesda  
**K. Hellström** Seattle  
**E. Klein** Stockholm  
**H. Kobayashi** Sapporo  
**M. Mastrangelo** Philadelphia  
**W. H. McBride** Edinburgh  
**M. Micksche** Vienna  
**P. Minden** La Jolla  
**M. Mitchell** Los Angeles  
**R. J. North** Saranac Lake  
**H. Ozer** Buffalo  
**G. Parmiani** Milano

**H. M. Pinedo** Amsterdam  
**P. Reizenstein** Stockholm  
**P. Rümke** Amsterdam  
**V. Schirmacher** Heidelberg  
**D. Scott** Rochester  
**F. Spreafico** Milan  
**F. Vänky** Stockholm  
**B. Vose** Cheshire  
**Y. Yagi** Kamakura City  
**K. Yamamoto** Kanazawa  
**Y. Yamamura** Osaka



**Springer International**

# Cancer Immunology Immunotherapy

## Other Biological Response Modifications

This journal was founded in 1976. Founding editor: G. Mathé

Editors: R. W. Baldwin, E. Mihich

Published by Springer International

### Copyright

*Submission of a manuscript implies:* that the work described has not been published before (except in the form of an abstract or as part of a published lecture, review, or thesis); that it is not under consideration for publication elsewhere; that its publication has been approved by all coauthors, if any, as well as by the responsible authorities at the institute where the work has been carried out; that, if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher; and that the manuscript will not be published elsewhere in any language without the consent of the copyright holders.

All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e.g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the publisher.

The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

While the advice and information in this journal is believed to be true and accurate at the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

*Special regulations for photocopies in the USA:* Photocopies may be made for personal or inhouse use beyond the limitations stipulated under Section 107 or 108 of U. S. Copyright Law, provided a fee is paid. This fee is US \$ 0.20 per page, or a minimum of US \$ 1.00 if an article contains fewer than five pages. All fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA, stating the ISSN 0340-7004, the volume, and the first and last page numbers of each article copied. The copyright owner's consent does not include copying for general distribution, promotion, new works, or resale. In these cases, specific written permission must first be obtained from the publisher.

### Other regulations

Authors publishing in this journal can, under certain conditions, benefit from library and photocopy fees collected by VG WORT. Authors of German nationality, and those resident in the Federal Republic of Germany or Berlin (West), as well as citizens of Austria, Switzerland and member countries of the European Community, may apply to Verwertungsgesellschaft WORT, Abteilung Wissenschaft, Goethestraße 49, D-8000 München 2, for detailed information.

Printed in Germany by E. Kieser GmbH Graphischer Betrieb, D-8902 Neusäß

© Springer-Verlag Berlin Heidelberg 1986

# Contents of volume 21

- Adam T, see Searle F, et al. 205  
 Adler A, see Eisenthal A, et al. 141  
 Ames FC, see Jessup JM, et al. 233  
 Aparisi T, see Ványk F, et al. 69  
 Austgulen R, see Kildahl-Andersen O, et al. 77
- Balsari A, Marolda R, Gambacorti-Passerini C, Sciorelli G, Tona G, Cosulich E, Taramelli D, Fossati G, Parmiani G, Cascinelli N: Systemic administration of autologous, alloactivated helper-enriched lymphocytes to patients with metastatic melanoma of the lung. A phase I study 148  
 Barrington-Leigh J, see Kadhim S 39  
 Beecham J, see Knauf S, et al. 217  
 Berényi E, Surányi P, Pálóczi K, Szegedi G: Large granular lymphocytes, Leu 7 reactivity and natural killer cell function in peripheral blood of patients with Hodgkin's disease 164  
 Blom U, see Blomgren H, et al. 31  
 Blomgren H, Blom U, Ullén H: Relation between the site of primary intracranial tumors and mitogenic responses of blood lymphocytes 31  
 Boden JA, see Searle F, et al. 205  
 Böök K, see Ványk F, et al. 69  
 Bras GE, see Klein WR, et al. 133  
 Braun DP, Harris JE: Effect of chemotherapy on NK function in the peripheral blood of cancer patients 240
- Cascinelli N, see Balsari A, et al. 148  
 Chiba I, see Yamashina K, et al. 45  
 Cosulich E, see Balsari A, et al. 148  
 Cudkowicz G, see Milisaukas VK, et al. 51
- de Jong WH, see Klein WR, et al. 133  
 Dekkers-Bijma AM, see Eggermont AM, et al. 81  
 Den Otter W: Immune surveillance and natural resistance: an evaluation 85  
 Drexler HG, Menon M, Gaedicke G, Minowada J: Reactivity patterns of monoclonal antibodies positive on myelomonocytic leukemia cells as defined by esterase isoenzyme analysis 188
- Eggermont AM, Weimar W, Tank B, Dekkers-Bijma AM, Marquet RL, Lameris JS, Westbroek DL, Jeekel J: Clinical and immunological evaluation of 20 patients with advanced colorectal cancer treated with high dose recombinant leukocyte interferon- $\alpha$  (rIFN $\alpha$ ) 81  
 Eisenthal A, Monselise J, Zinger R, Adler A: The effect of cimetidine on PBL from healthy donors and melanoma patients: Augmentation of T cell responses to TCGF mitogens and alloantigens and of TCGF production 141
- Fidler IJ, see Sone S, et al. 93  
 Fidler IJ: Optimization and limitations of systemic treatment of murine melanoma metastases with liposomes containing muramyl tripeptide phosphatidylethanolamine 169  
 Forbes JT, see Fraker LD, et al. 114  
 Fossati G, see Balsari A, et al. 148  
 Fraker LD, Halter SA, Forbes JT: Effects of orally administered retinol on natural killer cell activity in wild type BALB/c and congenitally athymic BALB/c mice 114  
 Fujiwara H, see Yoshioka T, et al. 193  
 Fukuzawa M, see Yoshioka T, et al. 193
- Gaedicke G, see Drexler HG, et al. 188  
 Gambacorti-Passerini C, see Balsari A, et al. 148  
 Gore VA, see Rowland GF, et al. 183  
 Goto M, see Nishimura T, et al. 12  
 Grazioli L, see Sensi M, et al. 199  
 Guarda L, see Jessup MJ, et al. 233
- Gubersky M, Thomson DMP, Lajzerowicz M: Expression by human fetal organs of organ specific cancer neoantigens as measured by leukocyte adherence inhibition 107
- Halter SA, see Fraker LD, et al. 114  
 Hamaoka T, see Yoshioka T, et al. 193  
 Harris JE, see Braun DP 240  
 Harwell LW, see Knauf S, et al. 217  
 Hashimoto Y, see Nishimura T, et al. 12  
 Helmkamp BF, see Knauf S, et al. 217  
 Herberman RB, see Zhang S-R, et al. 19  
 Herman J, Kew MC, Rabson AR: The effect of RU 41.740 (Biostim) on the production of interleukin-1 by monocytes and enriched large granular lymphocytes in normals and patients with hepatocellular carcinoma 26  
 Hughes LE, see Shukla HS, et al. 1  
 Hughes LE, see Shukla HS, et al. 6
- Ip MM, see Leung KH 161  
 Ivert T, see Ványk F, et al. 69
- Jeekel J, see Eggermont AM, et al. 81  
 Jessup JM, McBride CM, Ames FC, Guarda L, Ota DM, Romsdahl MM, Martin RG: Active specific immunotherapy of Dukes B<sub>2</sub> and C colorectal carcinoma: Comparison of two doses of the vaccine 233
- Kadhim S, Barrington-Leigh J: Correlation of tumor specific delayed type hypersensitivity reaction and tumor protection to SV<sub>40</sub>-induced mKSA fibrosarcoma 39  
 Kalwas J, see Knauf S, et al. 217  
 Kasai M, see Yamashina K, et al. 45  
 Kato S, see Yoshioka T, et al. 193  
 Kawakami K, see Shiiba K, et al. 119  
 Kersjes AW, see Klein WR, et al. 133  
 Kew MC, see Herman J, et al. 26  
 Kildahl-Andersen O, Austgulen R, Nissen-Meyer J: WEHI 164 sarcoma cells rendered resistant to monocyte-released cytotoxin are also resistant to monocyte-induced cytotoxicity 77  
 Kishino Y, see Mutsaers A, et al. 63  
 Klein E, see Ványk F, et al. 69  
 Klein WR, Bras GE, Misdorp W, Steerenberg PA, de Jong WH, Tiesjema RH, Kersjes AW, Ruitenberg EJ: Equine sarcoid: BCG immunotherapy compared to cryosurgery in a prospective randomised clinical trial 133  
 Knauf S, Kalwas J, Helmkamp BF, Harwell LW, Beecham J, Lord EM: Monoclonal antibodies against human ovarian tumor associated antigen NB/70K: Preparation and use in a radioimmunoassay for measuring NB/70K in serum 217  
 Kneale GW, Stewart AM, Wilson LMK: Immunizations against infectious diseases and childhood cancers 129  
 Kobayashi H, see Yamashina K, et al. 45  
 Kreicbergs A, see Ványk F, et al. 69  
 Kumagai K, see Shiiba K, et al. 119
- Lajzerowicz M, see Gubersky M, et al. 107  
 Lameris JS, see Eggermont AM, et al. 81  
 Leung KH, Ip MM: Effect of dietary polyunsaturated fat and 7,12-dimethylbenz(a)-anthracene on rat splenic natural killer cells and prostaglandin E synthesis 161  
 Liberman SN, see Webb KS, et al. 100  
 Lieberman AP, see Ware JL, et al. 58  
 Lopez-Berestein G, see Sone S, et al. 93  
 Lord EM, see Knauf S, et al. 217
- MacPherson GG, North RJ: Endotoxin-mediated necrosis and regression of established tumours in the mouse: A correlative study of quantitative changes in blood flow and ultrastructural morphology 209

- Marolda R, see Balsari A, et al. 148
- Marquet RL, see Eggermont AM, et al. 81
- Marsden CH, see Rowland GF, et al. 183
- Martin RG, see Jessup JM, et al. 233
- McBride CM, see Jessup JM, et al. 233
- McCormick KJ, Panje WR: Indomethacin-induced augmentation of lymphoproliferative responses in patients with head and neck cancer 226
- Menon M, see Drexler HG, et al. 188
- Milisauskas VK, Cudkowicz G, Nakamura I: Suppression of murine NK activity induced by *Corynebacterium parvum*: Further characterization and abrogation of suppressor cells 51
- Minowada J, see Drexler HG, et al. 188
- Misdorp W, see Klein WR, et al. 133
- Monseles J, see Eisenhalt A, et al. 141
- Morales A, Pang ASD: Experimental immunotherapy with NK-like cells. A preliminary report 156
- Mutsuura S, Sone S, Tsubura E, Tachibana K, Kishino Y: Activation of antitumor properties in alveolar macrophages from protein-calorie malnourished rats 63
- Naiki M, see Yamashina K, et al. 45
- Nakamura I, see Milisauskas VK, et al. 51
- Newcombe RG, see Shukla HS, et al. 1
- Newcombe RG, see Shukla HS, et al. 6
- Ngwenya BZ, Yamamoto N: Effects of inflammation products on immune systems. Lysophosphatidylcholine stimulates macrophages 174
- Nilsson U, see Vánky F, et al. 69
- Nishimura T, Togashi Y, Goto M, Yagi H, Uchiyama Y, Hashimoto Y: Augmentation of the therapeutic efficacy of adoptive tumor immunotherapy by in vivo administration of slowly released recombinant interleukin 2 12
- Nissen-Meyer J, see Kildahl-Andersen O, et al. 77
- North RJ, see MacPherson GG 77
- Ohuchi A, see Shiiba K, et al. 119
- Oikawa T, see Yamashina K, et al. 45
- Ota DM, see Jessup JM, et al. 233
- Pálóczi K, see Berényi E, et al. 164
- Pang ASD, see Morales A 156
- Panje WR, see McCormick KJ 226
- Parmiani G, see Sensi M, et al. 199
- Parmiani G, see Balsari A, et al. 148
- Péterffy Á, see Vánky F, et al. 69
- Rabson AR, see Herman J, et al. 26
- Romsdahl MM, see Jessup JM, et al. 233
- Rowland GF, Simmonds RG, Gore VA, Marsden CH, Smith W: Drug localisation and growth inhibition studies of vindesine-monoconal anti-CEA conjugates in a human tumour xenograft 183
- Ruitenberg EJ, see Klein WR, et al. 133
- Salup RR, see Zhang S-R, et al. 19
- Sciorelli G, see Balsari A, et al. 148
- Searle F, Adam T, Boden JA: Distribution of intact and Fab<sub>2</sub> fragments of anti-human chorionic gonadotrophin antibodies in nude mice bearing human choriocarcinoma xenografts 205
- Sensi M, Grazioli L, Parmiani G: Analysis of the cellular immune response to and adoptive immunotherapy of a BALB/c lymphoma that cross-reacts with normal DBA/2 cells 199
- Shiiba K, Suzuki R, Kawakami K, Ohuchi A, Kumagai K: Interleukin 2-activated killer cells: generation in collaboration with interferon and its suppression in cancer patients 119
- Shukla HS, Hughes LE, Whitehead RH, Newcombe RG: Long-term (5-11 years) follow-up of general immune competence in breast cancer. I. Pre-treatment levels with reference to micro-metastasis 1
- Shukla HS, Hughes LE, Whitehead RH, Newcombe RG: Long-term follow-up of general immune competence in breast cancer. II. Sequential pre- and post-treatment levels: A 10 year study 6
- Simmonds RG, see Rowland GF, et al. 183
- Smith W, see Rowland GF, et al. 183
- Sone S, see Mutsuura S, et al. 63
- Sone S, Lopez-Berestein G, Fidler IJ: Potential of direct antitumor cytotoxicity and production of tumor cytolytic factors in human blood monocytes by human recombinant interferon-gamma and muramyl dipeptide derivatives 93
- Steenenberg PA, see Klein WR, et al. 133
- Stewart AM, see Kneale GW, et al. 129
- Surányi P, see Berényi E, et al. 164
- Suzuki R, see Shiiba K, et al. 119
- Szegedi G, see Berényi E, et al. 164
- Tachibana K, see Mutsuura S, et al. 63
- Takai Y, see Yoshioka T, et al. 193
- Talmadge JE, see Zhang S-R, et al. 19
- Tank B, see Eggermont AM, et al. 81
- Taramelli D, see Balsari A, et al. 148
- Thomson DMP, see Gubersky M, et al. 107
- Tiesjema RH, see Klein WR, et al. 133
- Togashi Y, see Nishimura T, et al. 12
- Tona G, see Balsari A, et al. 148
- Tsubura E, see Mutsuura S, et al. 63
- Twilley TA, see Zhang S-R, et al. 19
- Uchiyama Y, see Nishimura T, et al. 12
- Ueda S, see Yoshioka T, et al. 193
- Ullén H, see Blomgren H, et al. 31
- Urias PE, see Zhang S-R, et al. 19
- Vánky F, Klein E, Willems J, Böök K, Ivert T, Péterffy Á, Nilsson U, Kreibergs A, Aparisi, T: Lysis of autologous tumor cells by blood lymphocytes tested at the time of surgery. Correlation with the postsurgical clinical course 69
- Wakamiya N, see Yoshioka T, et al. 193
- Walther PJ, see Webb KS, et al. 100
- Ware JL, Lieberman AP, Webb KS: Metastatic phenotype of human prostate tumor cells in athymic nude mice: Alteration by exposure to ethyl methanesulfonate and "Reversion" by 5-azacytidine 58
- Ware JL, see Webb KS, et al. 100
- Webb KS, see Ware JL, et al. 58
- Webb KS, Lieberman SN, Ware JL, Walther PJ: In vitro synergism between hybrid immunotoxins and chemotherapeutic drugs: relevance to immunotherapy of prostate carcinoma 100
- Weimar W, see Eggermont AM, et al. 81
- Westbroek DL, see Eggermont AM, et al. 81
- Whitehead RH, see Shukla HS, et al. 1
- Whitehead RH, see Shukla HS, et al. 6
- Willems J, see Vánky F, et al. 69
- Wilson LMK, see Kneale GW, et al. 129
- Wittrout RH, see Zhang S-R, et al. 19
- Yagi H, see Nishimura T, et al. 12
- Yamamoto N, see Ngwenya BZ, et al. 174
- Yamashina K, Oikawa T, Kasai M, Naiki M, Chiba I, Kobayashi H: Development of highly immunogenic variants of a rat fibrosarcoma line during in vitro cultivation 45
- Yoshioka T, Fukuzawa M, Takai Y, Wakamiya N, Ueda S, Kato S, Fujiwara H, Hamaoka T: The augmentation of tumor-specific immunity by virus help. III. Enhanced generation to tumor-specific Lyt-1+2- T cells is responsible for augmented tumor immunity in vivo 193
- Zhang S-R, Salup RR, Urias PE, Twilley TA, Talmadge JE, Herberman RB, Wittrout RH: Augmentation of NK activity and/or macrophage-mediated cytotoxicity in the liver by biological response modifiers including human recombinant interleukin 2 19
- Zinger R, see Eisenhalt A, et al. 141

# Subject index of volume 21

Antibody 205  
 - monoclonal 183, 188, 217  
 Antigen  
 - minor histocompatibility 199  
 - neo- 107

BCG 133  
 Biological response modifiers 19  
 Breast cancer 1, 6

Chemotherapy 240  
 - immuno 12, 100  
 Childhood cancer 129  
 Choriocarcinoma 205  
 Cimetidine 141  
 Colorectal cancer 81, 233  
*Corynebacterium parvum* 51  
 Cyclophosphamide 12  
 Cytotoxin 77

Dietary fat 161  
 DNCB 6

Endotoxin 209  
 Equine sarcoid 133

Fc receptor 174

Head and neck cancer 226  
*Hepatocellular carcinoma* 26  
 Hodgkin's disease 164  
 Hypersensitivity  
 - delayed type 39, 233

Immune competence 1, 6  
*Immune surveillance* 85  
 Immunochemotherapy 12, 100  
*Immunostimulants* 26  
 Immunotherapy 133, 148, 156, 233  
 - adoptive 12, 199  
*Immunotoxins* 100  
 Indomethacin 226  
*Interferon* 81, 93, 119  
 Interleukin 1 26  
 Interleukin 2 12, 19, 119, 141  
 Intracranial tumors 31

Leukemia 188  
 Leukocyte adherence 107  
 Liposomes 63, 169  
 Lymphocyte  
 - cytotoxicity 69, 77, 119  
 - helper 148  
 - mitogenic responses 31  
 - mixed tumor 233  
 - suppressor cells 51  
 Lymphoproliferative responses 226  
 Lysophosphatidylcholine 174

Macrophage  
 - activation 63, 93  
 - cytotoxicity 19, 63, 169  
 - stimulation 174  
 Melanoma 141, 148  
 Metastasis 1, 6, 58, 148, 169  
 Muramyl-dipeptide 93  
 Muramyl-tripeptide phosphatidylethanolamine 169

NK cells 19, 51, 114, 119, 156, 161, 164

Ovarian cancer 217

*Prostaglandin E* 161  
 Prostate tumor 58, 100

Radioimmunolocalisation 205

T cells 39, 141, 193  
 Tumor  
 - immunity 119, 193, 199  
 - immunogenic variants 45  
 - mixed lymphocyte responses 233

Vaccine virus 193  
 Vindesine antibody conjugates 183